论文部分内容阅读
目的:探讨丹红注射液对急性冠状动脉综合征病人内皮功能的保护作用。方法:采用随机对照方法将168例急性冠状动脉综合征患者分为两组,每组各84例。另选80例门诊体检的健康人作为正常组。常规治疗组根据ACS治疗指南用药;丹红组在给予常规药物治疗的基础上加用丹红注射液。治疗前后分别测定血浆内皮素(ETl)、一氧化氮(NO)超敏C反应蛋白(hsCRP)、白细胞介素-8(IL-8)和可溶性白细胞抗原40配体(sCD40L)。结果:两组患者治疗前ETl、NO、hsCRP、IL-8、ICAM-1无明显差异但与正常组有显著性差异;经14天治疗后,两组均有所下降,且丹红治疗组与常规治疗组问比较差异有统计学意义(P<0.01)。结论常规治疗的基础上加用丹红注射液可以更加显著的抑制血管内皮的炎症反应,改善ACS患者的血管内皮功能,从而稳定粥样斑块,改善预后。
Objective: To investigate the protective effect of Danhong injection on endothelial function in patients with acute coronary syndrome. Methods: 168 patients with acute coronary syndrome were randomly divided into two groups (n = 84 each). Another 80 outpatient physical examination of healthy people as a normal group. The conventional treatment group was treated according to the ACS treatment guidelines; Danhong group was given Danhong injection on the basis of conventional medical treatment. Plasma ET, hsCRP, IL-8 and sCD40L were measured before and after treatment. Results: There was no significant difference between ETL, NO, hsCRP, IL-8 and ICAM-1 before treatment in both groups, but there was significant difference between the two groups before treatment. After treatment for 14 days, both groups decreased, Compared with the conventional treatment group, the difference was statistically significant (P <0.01). Conclusion The conventional treatment based on the use of Danhong injection can be more significantly inhibited the inflammatory reaction of endothelial cells to improve vascular endothelial function in patients with ACS to stabilize atherosclerotic plaque and improve prognosis.